2019 Pipeline Review on Iron Deficiency Anemia (H1) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Iron
Deficiency Anemia – Pipeline Review, H1 2019” drug pipelines
has been added to ResearchAndMarkets.com’s offering.

Iron Deficiency Anemia – Pipeline Review, H1 2019
provides comprehensive information on the therapeutics under development
for Iron Deficiency Anemia (Hematological Disorders), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Iron Deficiency Anemia (Hematological
Disorders) pipeline guide also reviews of key players involved in
therapeutic development for Iron Deficiency Anemia and features dormant
and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Phase III, Phase II and Preclinical stages are 3,
3, 2 and 4 respectively. Similarly, the Universities portfolio in
Preclinical stages comprises 1 molecule, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Iron Deficiency Anemia (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Iron Deficiency
  Anemia (Hematological Disorders) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Iron Deficiency
  Anemia (Hematological Disorders) therapeutics and enlists all their
  major and minor projects.
• The pipeline guide evaluates Iron Deficiency Anemia (Hematological
  Disorders) therapeutics based on mechanism of action (MoA), drug
  target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Iron Deficiency Anemia (Hematological Disorders)

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Iron Deficiency Anemia (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Iron Deficiency Anemia (Hematological Disorders) pipeline depth and
  focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

• Jan 29, 2019: Positive results of long-term phase of AEGIS-CKD study
  further demonstrate the benefits of Feraccru
• Jan 24, 2019: Shield Therapeutics: Business and trading update
• Dec 13, 2018: Shield Therapeutics announces the US new drug
  application PDUFA date for Feraccru
• Dec 10, 2018: Rockwell Medical appoints new Vice President, Operations
• Dec 06, 2018: Clinical trial sheds new light on potential risk
  associated with intravenous iron treatment
• Dec 05, 2018: Shield Therapeutics notes UK launch of Feraccru by
  Norgine
• Dec 04, 2018: New study demonstrates significant difference between
  Iron Isomaltoside and Ferric Carboxymaltose on hypophosphatemic
  effects in a controlled, randomized clinical investigation
• Dec 03, 2018: Shield Therapeutics announces the new drug application
  for Feraccru has been accepted for filing and review by the FDA
• Oct 12, 2018: Rockwell Medical provides update on IV Triferic
• Oct 01, 2018: Shield Therapeutics announces submission of a New Drug
  Application (NDA) for Feraccru for the treatment of iron deficiency
  with the US Food and Drug Administration (FDA)
• Sep 13, 2018: Shield reports completion of recruitment to AEGIS Head
  to Head Study (AEGIS-H2H) comparing Feraccru with ferric carboxymaltose
• Sep 06, 2018: Monoferric receives marketing approval from Health Canada
• Jun 28, 2018: Shield Reports Recently Presented Supportive Data from
  Real-world Clinical use of Feraccru (Ferric Maltol)
• Jun 14, 2018: Shield reports positive top-line results from its
  AEGIS-PAED PK Paediatric Phase I Pharmacokinetics study of Feraccru
  (Ferric Maltol) in subjects with iron deficiency
• May 02, 2018: Rockwell Medical Announces Triferic Presentations at the
  2018 International Congress on Peritoneal Dialysis

Companies Mentioned

• Akebia Therapeutics Inc.
• Iron4u ApS
• Novartis AG
• Panion & BF Biotech Inc.
• Pharmacosmos AS
• Pieris Pharmaceuticals Inc.
• Rockwell Medical Inc.
• Shield Therapeutics PLC
• Vifor Pharma Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m5598

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematological
Drugs